ATORX Stock Overview
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Alligator Bioscience AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.04 |
| 52 Week High | kr1.57 |
| 52 Week Low | kr0.34 |
| Beta | 1.34 |
| 1 Month Change | 1.96% |
| 3 Month Change | -8.93% |
| 1 Year Change | -0.95% |
| 3 Year Change | -81.23% |
| 5 Year Change | -95.86% |
| Change since IPO | -97.27% |
Recent News & Updates
Recent updates
Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?
Dec 01
We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate
Dec 21Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?
Jul 30Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?
Jan 06Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation
Aug 18Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation
Apr 11Estimating The Intrinsic Value Of Alligator Bioscience AB (publ) (STO:ATORX)
Feb 17
Have Insiders Been Buying Alligator Bioscience AB (publ) (STO:ATORX) Shares?
Jan 13Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?
Dec 09Shareholder Returns
| ATORX | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 1.6% | -1.2% | -0.7% |
| 1Y | -1.0% | -5.1% | 8.7% |
Return vs Industry: ATORX exceeded the Swedish Biotechs industry which returned -6.3% over the past year.
Return vs Market: ATORX underperformed the Swedish Market which returned 8.1% over the past year.
Price Volatility
| ATORX volatility | |
|---|---|
| ATORX Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ATORX has not had significant price volatility in the past 3 months.
Volatility Over Time: ATORX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 58 | Søren Bregenholt | www.alligatorbioscience.se |
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company’s product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG
Alligator Bioscience AB (publ) Fundamentals Summary
| ATORX fundamental statistics | |
|---|---|
| Market cap | kr788.36m |
| Earnings (TTM) | -kr248.59m |
| Revenue (TTM) | kr59.25m |
13.3x
P/S Ratio-3.2x
P/E RatioIs ATORX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATORX income statement (TTM) | |
|---|---|
| Revenue | kr59.25m |
| Cost of Revenue | kr218.79m |
| Gross Profit | -kr159.54m |
| Other Expenses | kr89.05m |
| Earnings | -kr248.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | -0.33 |
| Gross Margin | -269.26% |
| Net Profit Margin | -419.55% |
| Debt/Equity Ratio | 0% |
How did ATORX perform over the long term?
See historical performance and comparison